Isomorphic Labs Raises $2.1B Led by Thrive Capital

Google DeepMind's AI drug discovery spinoff Isomorphic Labs has raised $2.1B in its second funding round led by Thrive Capital, following a $600M round in March 2025.

1 min read|agenticonsult Intelligence

Isomorphic Labs Raises $2.1B Led by Thrive Capital

Isomorphic Labs — the Google DeepMind spinoff applying AI to drug discovery, founded on the AlphaFold platform — has closed a $2.1 billion second funding round led by Thrive Capital, announced 2026-05-12. This follows a $600 million first round in March 2025. The company is scaling AI-driven small-molecule drug discovery, working in parallel with DeepMind's affiliated Isomorphic research on biochemistry adjacent to virtual-cell modelling.

Why It Matters

The $2.7B total raised in 14 months makes Isomorphic one of the best-capitalised AI life-sciences ventures globally, validating deep-tech AI bets in domains with clear objective functions — precisely the AlphaFold success criteria Demis Hassabis articulated this week.

Primary source

Reuters

This breaking-news item was assembled from the cited primary source with AI assistance. It is intended for rapid situational awareness — refer to the original publication for the definitive statement.

Isomorphic Labs Raises $2.1B Led by Thrive Capital

Isomorphic Labs Raises $2.1B Led by Thrive Capital

Why It Matters

Live Intel Feed